PMID- 22030746
OWN - NLM
STAT- MEDLINE
DCOM- 20120217
LR  - 20211203
IS  - 1527-3350 (Electronic)
IS  - 0270-9139 (Print)
IS  - 0270-9139 (Linking)
VI  - 55
IP  - 1
DP  - 2012 Jan
TI  - Stem cells in liver diseases and cancer: recent advances on the path to new 
      therapies.
PG  - 298-306
LID - 10.1002/hep.24762 [doi]
AB  - Stem cells have potential for therapy of liver diseases, but may also be involved 
      in the formation of liver cancer. Recently, the American Association for the 
      Study of Liver Diseases Henry M. and Lillian Stratton Basic Research Single Topic 
      Conference "Stem Cells in Liver Diseases and Cancer: Discovery and Promise" 
      brought together a diverse group of investigators to define the status of 
      research on stem cells and cancer stem cells in the liver and identify problems 
      and solutions on the path to clinical translation. This report summarizes the 
      outcomes of the conference and provides an update on recent research advances. 
      Progress in liver stem cell research includes isolation of primary liver 
      progenitor cells (LPCs), directed hepatocyte differentiation of primary LPCs and 
      pluripotent stem cells, findings of transdifferentiation, disease-specific 
      considerations for establishing a therapeutically effective cell mass, and 
      disease modeling in cell culture. Tumor-initiating stem-like cells (TISCs) that 
      emerge during chronic liver injury share the expression of signaling pathways, 
      including those organized around transforming growth factor beta and beta-catenin, 
      and surface markers with normal LPCs. Recent investigations of the role of TISCs 
      in hepatocellular carcinoma have provided insight into the transcriptional and 
      post-transcriptional regulation of hepatocarcinogenesis. Targeted chemotherapies 
      for TISC are in development as a means to overcome cellular resistance and 
      mechanisms driving disease progression in liver cancer.
CI  - Copyright (c) 2011 American Association for the Study of Liver Diseases.
FAU - Rountree, C Bart
AU  - Rountree CB
AD  - Department of Pediatrics and Pharmacology, Penn State College of Medicine, 
      Hershey, PA 17033, USA. crountree@hmc.psu.edu
FAU - Mishra, Lopa
AU  - Mishra L
FAU - Willenbring, Holger
AU  - Willenbring H
LA  - eng
GR  - R03DK088013/DK/NIDDK NIH HHS/United States
GR  - P01 CA130821/CA/NCI NIH HHS/United States
GR  - P30 DK026743/DK/NIDDK NIH HHS/United States
GR  - R01DK080852/DK/NIDDK NIH HHS/United States
GR  - R01 CA106614/CA/NCI NIH HHS/United States
GR  - P01CA130821/CA/NCI NIH HHS/United States
GR  - R01 CA042857/CA/NCI NIH HHS/United States
GR  - R01CA106614/CA/NCI NIH HHS/United States
GR  - R03 DK088013/DK/NIDDK NIH HHS/United States
GR  - R03 DK088013-02/DK/NIDDK NIH HHS/United States
GR  - P30DK026743/DK/NIDDK NIH HHS/United States
GR  - R01 DK080852/DK/NIDDK NIH HHS/United States
GR  - R01CA042857/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United States
TA  - Hepatology
JT  - Hepatology (Baltimore, Md.)
JID - 8302946
SB  - IM
MH  - Animals
MH  - Humans
MH  - Liver Diseases/pathology/therapy
MH  - Liver Neoplasms/*pathology/*therapy
MH  - Neoplastic Stem Cells/*pathology
MH  - Pluripotent Stem Cells/*cytology
MH  - Stem Cell Transplantation/*methods/trends
MH  - Translational Research, Biomedical/trends
PMC - PMC3245372
MID - NIHMS333465
EDAT- 2011/10/28 06:00
MHDA- 2012/02/18 06:00
PMCR- 2013/01/01
CRDT- 2011/10/28 06:00
PHST- 2011/10/28 06:00 [entrez]
PHST- 2011/10/28 06:00 [pubmed]
PHST- 2012/02/18 06:00 [medline]
PHST- 2013/01/01 00:00 [pmc-release]
AID - 10.1002/hep.24762 [doi]
PST - ppublish
SO  - Hepatology. 2012 Jan;55(1):298-306. doi: 10.1002/hep.24762.